Johnson & Johnson: 43.9% of patients in the Caplyta treatment group achieved a YMRS score improvement of at least 50% in week 3, and 23.7% in the placebo group.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.